CN1313470C - N-甲基苯并噻唑力复霉素的制备方法 - Google Patents
N-甲基苯并噻唑力复霉素的制备方法 Download PDFInfo
- Publication number
- CN1313470C CN1313470C CNB2004100162229A CN200410016222A CN1313470C CN 1313470 C CN1313470 C CN 1313470C CN B2004100162229 A CNB2004100162229 A CN B2004100162229A CN 200410016222 A CN200410016222 A CN 200410016222A CN 1313470 C CN1313470 C CN 1313470C
- Authority
- CN
- China
- Prior art keywords
- methylbenzothiazole
- formula
- rifomycin
- compound
- crude product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- PXDAXYDMZCYZNH-UHFFFAOYSA-N 3-methyl-2h-1,3-benzothiazole Chemical compound C1=CC=C2N(C)CSC2=C1 PXDAXYDMZCYZNH-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 24
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 claims description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 12
- 239000012043 crude product Substances 0.000 claims description 9
- 238000002425 crystallisation Methods 0.000 claims description 9
- 230000008025 crystallization Effects 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 8
- 229940043232 butyl acetate Drugs 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 7
- -1 N-methylbenzothiazole hydrazone Chemical class 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 3
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- BYGOPQKDHGXNCD-UHFFFAOYSA-N tripotassium;iron(3+);hexacyanide Chemical compound [K+].[K+].[K+].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] BYGOPQKDHGXNCD-UHFFFAOYSA-N 0.000 claims description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 3
- 238000006722 reduction reaction Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 241000894006 Bacteria Species 0.000 abstract description 6
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 6
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract description 4
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 238000001228 spectrum Methods 0.000 abstract description 4
- 241000192125 Firmicutes Species 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000002147 killing effect Effects 0.000 abstract 1
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 11
- 229960001225 rifampicin Drugs 0.000 description 11
- 238000003756 stirring Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 238000011026 diafiltration Methods 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 201000008827 tuberculosis Diseases 0.000 description 4
- 206010024229 Leprosy Diseases 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229910000108 silver(I,III) oxide Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 241000187492 Mycobacterium marinum Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000000814 tuberculostatic agent Substances 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010024227 Lepromatous leprosy Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 229930183506 Pluramycin Natural products 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- BQCHGWYGWQEMTJ-YLGMGCDCSA-N [(2r,3r,4s,6r)-4-(dimethylamino)-6-[8-[(2s,4s,5r,6r)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2-yl]-11-hydroxy-5-methyl-2-[2-methyl-3-[(z)-prop-1-enyl]oxiran-2-yl]-4,7,12-trioxonaphtho[2,3-h]chromen-10-yl]-2,4-dimethyloxan-3-yl] acetate Chemical compound C\C=C/C1OC1(C)C1=CC(=O)C2=C(C)C=C(C(=O)C=3C(=C(O)C([C@@H]4O[C@H](C)[C@H](OC(C)=O)[C@](C)(C4)N(C)C)=CC=3[C@H]3O[C@H](C)[C@H](O)[C@H](C3)N(C)C)C3=O)C3=C2O1 BQCHGWYGWQEMTJ-YLGMGCDCSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000015305 multibacillary leprosy Diseases 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
菌名 | 培养基 | M.I.C(R75-1)(γ/ml) | M.I.C(力复平)(γ/ml) | 备注 |
金黄色葡萄球菌209ρ | / | 0.0031 | 0.0031 | |
耐其他抗生素全葡1支 | / | 0.0031 | 0.0031 | |
耐力复霉素SV全葡1支 | / | 0.25 | >100 | |
大肠杆菌单分技杆菌607 | 培养28小时培养48小时培养72小时 | 100<0.0470.0950.095 | 6.250.0950.2512.5 | |
强毒人型结核 | 苏通 | <0.01 | 0.025 | |
杆菌H37RV | 苏通加血清 | 2.5-5 | 5 | |
杆菌H37RV | 苏通加血清 | 2.5-5 | 5 | |
鸟型结核杆菌 | 苏通 | <0.25 | <0.25 | |
海鱼分枝杆菌 | 苏通 | <0.01 | 0.1 | |
海鱼分枝杆菌 | 苏通加血清 | 0.5 | 1 |
粗晶用量 | 氯仿用量 | 其他溶媒用量 | 重结晶得量(g) | 备注 |
1克 | 3ml | 丙酮6ml | 0.7g | |
1克 | 3ml | 乙醇3ml | 0.9g | |
1克 | EA15ml加热溶解,冷后析出 | 0.7g | ||
1克 | 四氢呋喃5ml加热溶解冷后析出 | 0.7g |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100162229A CN1313470C (zh) | 2004-02-11 | 2004-02-11 | N-甲基苯并噻唑力复霉素的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100162229A CN1313470C (zh) | 2004-02-11 | 2004-02-11 | N-甲基苯并噻唑力复霉素的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1654467A CN1654467A (zh) | 2005-08-17 |
CN1313470C true CN1313470C (zh) | 2007-05-02 |
Family
ID=34892210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100162229A Expired - Lifetime CN1313470C (zh) | 2004-02-11 | 2004-02-11 | N-甲基苯并噻唑力复霉素的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1313470C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103951677B (zh) * | 2014-03-17 | 2016-04-06 | 四川省长征药业股份有限公司 | 利福喷丁的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1006694B (zh) * | 1984-11-29 | 1990-02-07 | 川崎制铁株式会社 | 改进了可焊性的表面处理钢带及其制造方法 |
-
2004
- 2004-02-11 CN CNB2004100162229A patent/CN1313470C/zh not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1006694B (zh) * | 1984-11-29 | 1990-02-07 | 川崎制铁株式会社 | 改进了可焊性的表面处理钢带及其制造方法 |
Non-Patent Citations (1)
Title |
---|
利福霉素类半合成抗生素的研究概况 游金莺,中国抗生素杂志,第4期 1985 * |
Also Published As
Publication number | Publication date |
---|---|
CN1654467A (zh) | 2005-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1174991C (zh) | 克拉霉素的o型结晶 | |
CN1217951C (zh) | 克拉霉素多晶型物的制备方法和新的多晶型物iv | |
CN1733708A (zh) | 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用 | |
CA2934523A1 (en) | Phenazine derivatives as antimicrobial agents | |
WO2006081771A1 (fr) | Dérivés d'artémisine (qinghaosu), méthodes de synthèse et applications, et préparations pharmaceutiques contenant lesdits dérivés | |
CN1974569A (zh) | 8-辛基小檗碱盐酸盐、合成方法及应用 | |
JPS61210085A (ja) | 免疫調節剤として有効なイミダゾ〔4,5−f〕キノリン | |
CN1313470C (zh) | N-甲基苯并噻唑力复霉素的制备方法 | |
CN106511351B (zh) | 聚普瑞锌在制备抗幽门螺旋杆菌药物中的应用 | |
CN112341402A (zh) | 一种可用于医疗护理过程中抑菌的嘧啶类化合物的制备方法及应用 | |
CN115785070B (zh) | 一种吡咯烷基乙酰胺衍生物、制备方法及其应用 | |
CN110049973B (zh) | 1,4-二苯基-1h-咪唑和2,4-二苯基噻唑类衍生物及其制备方法和用途 | |
CN1810777A (zh) | 一类治疗或预防细菌感染的化合物及其制备方法和用途 | |
CN1533776A (zh) | N-乙酰氨基葡萄糖在制备用于治疗病毒或细菌感染所致的局部损伤和全身症状的药物中的应用 | |
CN1868451A (zh) | 卡德沙星注射制剂及其制备方法 | |
CN111187226B (zh) | 一种特异性杀伤革兰氏阴性菌的化合物及制备方法和应用 | |
CN109206463A (zh) | 一种罗红霉素晶型化合物及其制备方法 | |
CN1742742A (zh) | 阿米卡星软膏及其制备方法和应用 | |
AU2009223841A1 (en) | Fullerene therapies for inflammation | |
CN114031635B (zh) | 一种二氟硼姜黄素衍生物及其制备方法和应用 | |
CN1231216C (zh) | 门冬氨酸洛美沙星粉剂及其制备方法 | |
CN1842531A (zh) | 1-甲基碳青霉烯化合物的结晶 | |
CN1742996A (zh) | 肠三叶因子口服制剂及其临床应用 | |
CN1623993A (zh) | 新型的斑蝥胺和去甲斑蝥胺衍生物及其在医药中的应用 | |
CN1830424A (zh) | 盐酸特比萘芬栓剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI XINYA PHARMACEUTICAL INDUSTRY CO. LTD. Free format text: FORMER OWNER: SHANGHAI XINXIANFENG PHARMACEUTICAL CO., LTD. Effective date: 20131211 Free format text: FORMER OWNER: SHANGHAI MEDICINE SCIENCE + TECHNOLOGY DEVELOPING CO., LTD. Effective date: 20131211 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201203 PUDONG NEW AREA, SHANGHAI TO: 201209 PUDONG NEW AREA, SHANGHAI |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131211 Address after: 201209 Chuansha Road, Shanghai, No. 978, No. Patentee after: SHANGHAI XINYA PHARMACEUTICAL CO.,LTD. Address before: 201203 92 Zhangjiang Road, Shanghai, Pudong Patentee before: Shanghai Asia Pioneer Pharmaceutical Co.,Ltd. Patentee before: Shanghai Pharmaceutical Technology Development Co.,Ltd. |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 201209 Chuansha Road, Shanghai, No. 978, No. Patentee after: SHANGHAI PHARMA XINYA PHARMACEUTICAL CO.,LTD. Address before: 201209 Chuansha Road, Shanghai, No. 978, No. Patentee before: SHANGHAI XINYA PHARMACEUTICAL CO.,LTD. |
|
CX01 | Expiry of patent term |
Granted publication date: 20070502 |
|
CX01 | Expiry of patent term |